Stereotaxis announced on July 1, 2025, the publication of initial clinical results using its MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. The peer-reviewed article, titled 'First In‑Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter,' provides the first scientific literature supporting the efficacy and safety of the MAGiC catheter.
The prospective multi-center, single-arm study included an initial analysis of acute efficacy and safety for 67 patients treated for a broad spectrum of arrhythmias in all four heart chambers. The study demonstrated an acute efficacy of 94% for MAGiC, which compares favorably to results from larger ablation registries using other catheters. Procedure time averaged 83 minutes skin-to-skin.
The study authors, with extensive experience in robotic procedures, noted the improved stability of MAGiC, the absence of need for sheaths for catheter support, steady catheter tip temperatures during ablation, and low irrigation rates. A procedure-related adverse event rate of 1.5% was reported, reflecting known risks of RF ablation and not attributed to catheter malfunction. These findings support the ongoing launch of MAGiC across Europe.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.